Diaxonhit discovers and commercializes specialty diagnostic products in the transplantation, infectious diseases, and cancer diagnosis specialty areas. Its commercialized product includes Tétanos Quick Stick, a proprietary test, which is used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products comprise the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product includes AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also involved in the development of companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. Diaxonhit was founded in 1997 and is headquartered in Paris, France.
diaxonhit (ALEHT:Euronext Paris)
65 Boulevard Masséna
Phone: 33 1 53 94 77 00
Fax: 33 1 53 94 77 07www.exonhit.com
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact DIAXONHIT, please visit www.exonhit.com. Company data is provided by Capital IQ. Please use this form to report any data issues.